Date: Presenter: Ryan Chen

Slides:



Advertisements
Similar presentations
Unstable angina and NSTEMI
Advertisements

Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
April 25 Exam April 27 (bring calculator with exp) Cox-Regression
Modeling clustered survival data The different approaches.
1 Primary Angioplasty for Acute STEMI Dr Adam Jacques Dr Sola Odemuyiwa February 2010.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Primary Care Acute Chest Pain Awareness. Background BHF Funded Mid & South West Wales Project –Report from MINAP (Myocardial Ischaemia National Audit.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
RISK FACTORS AND HOSPITAL MORTALITY IN STEMI: MULTICENTER STUDY AUTHORS: I. Santos Rodríguez 1, G. Perez Ojeda 2, N. Alonso Orcajo 3, S. Estrada Gómez.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Myocardial Ischaemia National Audit Project Are we replacing good fibrinolytic treatment with poor primary PCI? John Birkhead who has NO CONFLICT OF INTEREST.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
AA 2008 Session III: STEMI The UK data Mark de Belder The James Cook University Hospital Middlesbrough.
Lysis and Beyond: ESC Guidelines and Reality J N Townend Queen Elizabeth Hospital Birmingham.
Acute Coronary Syndromes SIGN 93. MINAP Mortality after Acute Coronary Syndromes Cumulative: 13.6% Blue 10.6% Green 11.6% Red.
Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparative Effectiveness of Rhythm Control vs Rate.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.
Support for implementing NICE guidance: Unstable angina and NSTEMI Unstable angina and NSTEMI, CG94, rd Edition March 2014.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nuisance Bleeding With Prolonged Dual Antiplatelet.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
MINAP: MINAP: Equity of Access in the National Databases in Wales? Swansea University/ABMU, NICOR Swansea University/ABMU,
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Associate Professor, Honorary Consultant Cardiologist
an open, prospective, randomized, multicentre trial
A Clinical profile of patients enrolled in the Pakistan ACS registry
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study Kirchgesner J, et al. Gut 2017;0:1–8.
Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:
Anastasiia Raievska (Veramed)
Risk stratification in ACS F.Shakib .cardiologigst
The British Heart Foundation older patients with non-ST SEgmeNt elevatIOn myocaRdial infarction Randomized Interventional TreAtment Trial The BHF SENIOR-RITA.
Figure 1 Patient flow chart.
Copyright © 2012 American Medical Association. All rights reserved.
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Lancet. 2017 Aug 5;390(10094): doi: /S (17) Epub 2017 May 25.
Improved Outcomes in Patients with Non-ST-Elevation Myocardial Infarction during 20 Years are Related to Implementation of Evidence-based Treatments –
Copyright © 2009 American Medical Association. All rights reserved.
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
Circ Cardiovasc Interv
Presenter: Wen-Ching Lan Date: 2018/05/09
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng,
Baseline characteristics of patients
European Heart Association Journal 2007 April
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
Press Conference Title
Risk adjustment using administrative and clinical data: model comparison
Figure 1 PCI strategies in patients with STEMI and multivessel disease
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
Figure 4 Observational studies on multiple treatment strategies
Global Registry of Acute Coronary Events: GRACE
Institute of Cardiology
China PEACE risk estimation tool for in-hospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic.
Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.
Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J
Urban–Rural Comparisons in Hospital Admission, Treatments, and Outcomes for ST-Segment–Elevation Myocardial Infarction in China From 2001 to 2011 A Retrospective.
National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the.
Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes: A Cross-sectional Study Shi Zhao, Karthik.
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
MRRs and EMRRs for women with ACS
A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.
Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE-Retrospective AMI Study Yan Gao, Frederick.
16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.
Kaplan-Meier survival curves and the log rank test
Presentation transcript:

Date: 2017.01.10 Presenter: Ryan Chen Multilevel mixed-effects parametric survival models Date: 2017.01.10 Presenter: Ryan Chen

Date: 2017.01.10 Presenter: Ryan Chen Multilevel mixed-effects parametric survival models Date: 2017.01.10 Presenter: Ryan Chen

16 January 2014

Objective To investigate temporal changes in survival after acute myocardial infarction (AMI) by early invasive strategy. Background It is not known how survival has changed over time for patients who do and do not receive an early invasive strategy for the management of AMI. This study, therefore, aimed to investigate the temporal trends in hospital treatments, including revascularisation, and 6-month survival rates after AMI.

Study design Myocardial Ischaemia National Audit Project (MINAP) between 1 January 2003 and 31 July 2011. multicentre prospective registry of patients hospitalised in England and Wales.

Study design-2 We compared survival rates between groups of patients admitted to hospital for 2003–2004, 2005–2006, 2007–2008 and 2009–2010. We based our analyses on the diagnosis made at hospital discharge of the phenotype of AMI. We stratified the management of STEMI by the provision of acute reperfusion therapy (which was defined as PPCI and/or thrombolysis), and the management of NSTEMI by the provision of coronary angiography.

Covariates Validated mini-Global Registry of Acute Coronary Events (GRACE) 6-month risk score was calculated. For patients with AMI, treating hospitals were ranked based on quartiles (Q1–Q4) the number of coronary angiograms (but not primary PCI cases) the number of PPCI cases.

Statistical methods Survival time was calculated from the date of admission to hospital to the date of death up to 6 months. We identified an elevated risk of mortality within 30 days of AMI, and therefore survival was studied with adjustment for this early mortality using Weibull accelerated failure-time regression models (AFT model). PH model VS. AFT model

Statistical methods-2 Models were fitted by age group (<65, 65–80, >80 years), sex, type of AMI (STEMI vs NSTEMI) and by biennial period of admission to hospital (2003–2004, 2005– 2006, 2007–2008 and 2009–2010). Patients were clustered by hospitals; therefore, to allow for variations at the hospital level, random effects (shared frailty) models were fitted. Shared Frailty model VS. Stratified Cox model

Statistical methods-3 Regression model parameter estimates were represented by time ratios (TR) and 95% CI and can be construed as the relative change in survival over time. Relative survival as a measure of cause-specific survival. Excess mortality was considered as the mortality attributable to the index AMI.

CONCLUSIONS Survival rates after AMI have improved. Whereas survival estimates for STEMI patients who did not receive reperfusion therapy were stable, they worsened for NSTEMI patients not receiving coronary angiography.

Mixed-effects survival models contain both fixed effects and random effects. random effects are useful for modeling intracluster correlation. adjusting survivor functions accelerated failure-time (AFT) model Proportional hazards (PH) model. mestreg is suitable only for data that have been stset. appropriate for data exhibiting multiple records per subject and time- varying covariates

Mixed-effects survival models

Mixed-effects survival models

Mixed-effects survival models

Each test is identified by tid. Occasion: indicate the times. E.g. 1,2,3,4 Treat: Major independent variable. Pid: Patients’ id.